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Summary
BACKGROUND: The Kilombero and Ulanga Antiretroviral
Cohort (KIULARCO) is a single-site, open and ongoing
prospective cohort of people living with human immunode-
ficiency virus (PLWHIV) established in 2005 at the Chronic
Diseases Clinic of Ifakara (CDCI), within the Saint Francis
Referral Hospital (SFRH) in Ifakara, Tanzania. The objec-
tives of KIULARCO are to (i) provide patient and cohort-
level information on the outcomes of HIV treatment; (ii)
provide cohort-level information on opportunistic infections
and comorbidities; (iii) evaluate aspects of human immun-
odeficiency virus (HIV) care and treatment that have na-
tional or international policy relevance; (iv) provide a plat-
form for studies on improving HIV care and treatment in
sub-Saharan Africa; and (v) contribute to generating lo-
cal capacity to deal with the challenges posed by the HIV/
AIDS pandemic in this region. Moreover, KIULARCO may
serve as a model for other healthcare settings in rural sub-
Saharan Africa.
METHODS: Since 2005, all patients diagnosed with HIV
at the Saint Francis Referral Hospital are invited to partici-
pate in the cohort, including non-pregnant adults, pregnant
women, adolescents, children and infants. The information
collected includes demographics, baseline and follow-up
clinical data, laboratory data, medication history, drug tox-
icities, diagnoses and outcomes. Real-time data are cap-
tured during the patient encounter through an electronic
medical record system that allowed transition to a paper-
less clinic in 2013. In addition, KIULARCO is associated
with a biobank of cryopreserved plasma samples and cell
pellets collected from all participants before and at differ-
ent time-points during antiretroviral treatment.
RESULTS: Up to the end of 2016, 12 185 PLWHIV have
been seen at the CDCI; 9218 (76%) of whom have been
enrolled into KIULARCO and 6965 (76%) of these have
received ART from the clinic. Patients on ART attend at
least every 3 months, with laboratory monitoring every 6
months. KIULARCO data have been used to generate rel-
evant information regarding ART outcomes, opportunistic
infections, non-AIDS comorbidities, prevention of mother-
to-child transmission of HIV, paediatric HIV, and mortal-
ity and retention in care. Requests for collaborations on
analyses can be submitted to the KIULARCO scientific
committee.
CONCLUSIONS: KIULARCO provides a framework for
improving the quality of care of people living with HIV in
sub-Saharan Africa, to generate relevant information to
evaluate ART programmes and to build local capacity to
deal with HIV/AIDS. The comprehensiveness of the da-
ta collected, together with the biobank spanning over ten
years has created a unique research platform in rural sub-
Saharan Africa.
Keywords: HIV, AIDS, sub-Saharan Africa, cohort stud-
ies,
Introduction
The human immunodeficiency virus / acquired immunod-
eficiency syndrome (HIV/AIDS) pandemic is one of the
worst epidemics in human history, having affected more
than 70 million people and claimed the lives of 35 million
[1]. Sub-Saharan Africa (SSA) continues to bear a dis-
proportionate share of the global HIV burden. The efforts
made in the last decade have resulted in previously
unimaginable access to antiretroviral treatment (ART),
prevention services, and evidence-based care interventions
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for people living with HIV/AIDS (PLWHIV) in Africa,
leading to a subsequent stabilisation of the epidemic in
the continent. However, of the estimated 36.7 million
PLWHIV worldwide in 2015, 70% (25.5 million) were in
SSA [2]. New infections and AIDS-related deaths were al-
so disproportionately concentrated in SSA, accounting for
65% (1.4 million) of the 2.1 million new infections and
74% (800 000) of the 1.1 million AIDS-related deaths in
2015 [2]. Remarkably, within SSA, the HIV epidemics still
differ greatly between countries, with Southern and East-
ern Africa being the most heavily affected regions.
Despite the success in scaling up ART, with over 17 mil-
lion people treated, and the stabilisation of the epidemic in
SSA, many challenges persist. ART scale-up programmes
in Africa are hindered by late diagnosis of HIV infection
[3], low rates of linkage into care [4], obstacles in treat-
ment delivery [5], low availability of virological and drug
resistance monitoring [6], and low long-term retention in
care [7]. Other relevant challenges include logistical fac-
tors disrupting care and undermining the success of ART
scale-up programmes, the neglected epidemic among key
populations, and the ageing of the HIV-infected popula-
tion.
In Tanzania, 1.4 million people were estimated to live with
HIV in 2015 [8]. The national AIDS control programme
was launched in 2004 in response to the rising epidem-
ic and, since then, the HIV prevalence in Tanzania has
declined from 7.0% to 4.7% among adults aged 15–49
years [8]. However, the HIV prevalence remains highly
heterogeneous, with geographical and population variabil-
ity. In addition, the HIV prevalence among key popula-
tions, such as men who have sex with men, people who in-
ject drugs and female sex workers, remains unacceptably
high at 12.3–41.0%, 34.8–42.0% and 31.4%, respectively
[9]. The ART coverage in 2015 was 53% in adults and
56% in children [8]. Since 2016, Tanzania has progressive-
ly adopted the 2015 WHO recommendations of treating all
PLWHIV regardless of CD4 cell counts.
Prospective cohort studies have been fundamental for de-
scribing the natural history of HIV infection, determining
factors and biomarkers associated with disease progression
and evaluating treatment efficacy. Given the continuously
changing face of the HIV epidemic in Africa, there is a
need for large representative cohort databases with com-
prehensive patient-level data in order to generate evidence
on ART outcomes and complications to inform national
and international health policy and improve HIV care and
treatment nationally and globally. There are excellent HIV
cohorts in SSA [10–16], but there is a paucity of obser-
vational prospective long-term cohort data on PLWHIV in
Tanzania and overall in rural settings in SSA. The Tanzan-
ian national AIDS control programme provides relevant
national data with good coverage across the country, but
with limited clinical depth [17–20].
In this article, we aim to describe the Kilombero and Ulan-
ga Antiretroviral Cohort (KIULARCO) as a model for a
large prospective cohort in SSA. KIULARCO is integrated
within routine clinical care delivered through the national
health care system, and generates daily extensive clinical
and epidemiological data in real-time through an electron-
ic data collection system tailored to the specific needs of
rural sub-Saharan Africa.
Cohort description
KIULARCO is a single-site, open, ongoing and prospec-
tive cohort of PLWHIV based at the Chronic Diseases
Clinic of Ifakara (CDCI), within the Saint Francis Referral
Hospital in Ifakara, Tanzania. The CDCI was started in
2004 as a public-sector HIV care and treatment centre of
the Ministry of Health and Social Welfare of the Govern-
ment of Tanzania, being the first rural HIV care and treat-
ment clinic accredited to provide HIV services through
the Tanzanian national AIDS control programme. From
its conception, the CDCI has received continuous support
from the Swiss Tropical and Public Health Institute (Swiss
TPH, Basel, Switzerland), the Ifakara Health Institute (IHI,
Tanzania), the Department of Infectious Diseases and Hos-
pital Epidemiology of the University Hospital Basel
(Basel, Switzerland) and the Department of Infectious Dis-
eases of the University Hospital Bern (Bern, Switzerland).
KIULARCO was developed originally in 2005 for moni-
toring and evaluating ART roll-out. The current objectives
of the KIULARCO cohort are to: (i) provide patient and
cohort-level information on the outcomes of HIV treat-
ment; (ii) provide cohort-level information on opportunis-
tic infections and non-AIDS comorbidities; (iii) evaluate
aspects of HIV care and treatment that have national or
international policy relevance; (iv) provide a platform for
studies on improving HIV care and treatment, including
clinical trials; and (v) contribute to generating local capaci-
ty to deal with the challenges posed by the HIV/AIDS pan-
demic in SSA.
All individuals diagnosed with HIV at the Saint Francis
Referral Hospital, and those diagnosed elsewhere and
coming for care at the CDCI, are invited to participate in
KIULARCO. Blood samples are drawn at routine visits
prior to and 3 months after ART initiation, and every 6
months thereafter, and plasma and cell pellets are cryopre-
served at ˗80ºC and ˗20°C.
The Ifakara Health Institute institutional review board and
the Health Research Ethics Review Committee of the Na-
tional Institute for Medical Research of Tanzania provide
ethical approval for KIULARCO, including for sample
collection, cryopreservation and analysis of collected data.
Written informed consent is sought from all participants at
registration at the CDCI; for children and adolescents aged
<18 years, informed consent is sought from caregivers. Da-
ta are backed up daily, stored on a secure local server and
de-identified before analysis.
Setting
The rural districts of Kilombero and Ulanga, in the Mo-
rogoro region of south East Tanzania, have a population
of approximately 700 000 [21] and an estimated 40 000
PLWHIV. The Saint Francis referral Hospital is the largest
health facility in the Kilombero district, located in its main
town, Ifakara, and serving as the referral hospital of seven
primary healthcare clinics and HIV care and treatment cen-
tres (fig. 1). The Ifakara Health Institute runs two health
demographic surveillance systems in the area: one rural,
covering 25 villages in Ulanga and Kilombero districts,
comprising 126 836 people; one urban consisting of five
areas of Ifakara town, with 44 992 people [22]. The main
economic activity in the Kilombero and Ulanga districts is
subsistence farming, especially of rice, with smaller pro-
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portions of pastoralists who migrated into the area from
the north and centre of Tanzania. In Ifakara town, the eco-
nomic activity is centred on agricultural trade, farming
and provision of higher education, especially in the bio-
medical field. There are five biomedical institutions that
constitute the so-called Ifakara cluster, including besides
the Ifakara Health Institute and the Saint Francis Referral
Hospital: the Tanzanian Training Centre for International
Health (www.ttcih.org), the Saint Francis University Col-
lege on Health and Allied Sciences (sfuchas.ac.tz/ifakara/)
and the Edgar Maranta School of Nursing (ifakaranurs-
ing.ac.tz).
People from more than 70 ethnic groups currently reside in
Ifakara, 60% of whom are in-migrants to the area. Swahili
is the main language of communication and English is also
spoken by professionals working in the Ifakara cluster. The
population structure is typical of rural African populations,
with 46% of people younger than 15 years of age [22].
The population in both districts shows net out-migration
for young men, mainly to find employment in more ur-
banised areas, leading to difficulties in retention in care of
PLWHIV. Moreover, the increasing population movements
may affect HIV dynamics in the area, and the recent con-
struction of a bridge over the Kilombero River, together
with the opening of a north-south road is expected to con-
tribute to further changes in the mid-term.
The multidisciplinary skills available at the Ifakara Health
Institute, coupled with the unique position of the CDCI
in a cluster of research, health service delivery and health
training organisations, allow for research along the entire
pipeline of intervention development to impact evaluation.
Enrolment of participants
Since 2004, voluntary counselling and testing services are
available to anybody willing to be tested for HIV. In ad-
Figure 1: Catchment area of KIULARCO, Kilombero and Ulanga
Districts (ArcGIS software, ESRI, USA).
dition, since 2014, all persons attending the outpatient de-
partment, antenatal clinic and hospital wards are consis-
tently offered an HIV test through provider-initiated test-
ing and counselling services. Group pre-test and individu-
alised post-test counselling are given. All HIV-positive pa-
tients are invited to join KIULARCO, including non-preg-
nant adults, pregnant women, adolescents, children and
infants. Reasons for not being enrolled include consent re-
fusal, being regularly attended in another clinic, and fore-
seen short-term attendance to the CDCI. To the end of
2016, 12 185 PLWHIV have been seen at the CDCI; 9218
(76%) of whom have been enrolled into KIULARCO and
6965 (76%) of these have received ART from the clinic
(fig. 2).
The main characteristics of the adult and child populations
at enrolment into the cohort are summarised in table 1.
Data collection
Before 2013, the data collected was limited to the para-
meters recommended by the Ministry of Health and So-
cial Welfare of Tanzania for monitoring of the HIV pro-
gramme. Records were kept on paper and entered into an
electronic database. Examples of the early use of KIU-
LARCO data were studies on voluntary counselling and
testing [23] and ART outcomes [24]. In December 2012,
an optimised data collection system was implemented, al-
lowing for the progressive transition to a paperless clinic,
effective as of June 2013. This system serves clinical data
documentation and harmonisation of the data collection
among CDCI clinicians, and provides the basis for analysis
and a better understanding of different aspects of the daily
clinical and operational challenges. The CDCI, the phar-
macy and the laboratory are interconnected through this
system, which has improved the efficiency of the patients’
circuits, reducing the waiting times and increasing the pa-
tients’ satisfaction. Real-time data at the time of the patient
encounter is captured through a specifically designed inter-
face based on Open Medical Record System (www.open-
mrs.org) to meet both clinical and research needs. Table 2
summarises the variables routinely collected in KIULAR-
CO since 2013.
The flow of patients at the CDCI is designed to accelerate
ART initiation and to minimise losses to follow up be-
tween HIV diagnosis and treatment, which is one of the
Figure 2: Number of patients enrolled per year in KIULARCO be-
tween 2005 and 2016.
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main factors affecting attrition in SSA [25]. On the day of
HIV diagnosis, after post-test counselling, patients are reg-
istered at the CDCI and referred to the laboratory, where
blood is withdrawn for the assessment of the baseline lab-
oratory parameters. The baseline clinical visit is scheduled
for the next working day, so the clinician has all laboratory
results available. During the baseline clinical visit, a thor-
ough medical history and physical examination are record-
ed (table 2). Full blood counts, liver and renal function
tests, as well as screening results for opportunistic infec-
Table 1: Summary of baseline characteristics of participants enrolled in KIULARCO from 2005 to 2016.
Child(<15 years old) Adult(≥15 years old) Total 1
No. 813 (100%) 8376 (100%) 9218 (100%)
Age, years 5 (2–8) 38 (31–45) 36 (29–44)
Sex, female 2 390 (48%) 5395 (65%) 5788 (63%)
Distance from home to clinic, km 3 25 (1–70) 5 (1–51) 5 (1–51)
Marital status, married/cohabiting 4 – 4466 (54%) –
Education, none/primary school only 5 – 4444 (94%) –
Pregnant 6 – 306 (8%) –
Partner status 7
Positive – 1125 (14%) –
Negative – 586 (7%) –
Not tested – 2395 (30%) –
Unknown – 2888 (37%) –
Not applicable – 861 (11%) –
Disclosure of HIV status, yes 8 – 4668 (69%) –
Time from HIV diagnosis to enrolment, days 9 7 (1–43) 8 (1–49) 8 (1–48)
BMI, kg/m2 10
Underweight (<18.5) – 1746 (25%) –
Normal (18.5–<25) – 4155 (60%) –
Overweight (25–<30) – 834 (12%) –
Obese (≥30) – 241 (3%) –
WHO stage 11
1 233 (30%) 3021 (38%) 3261 (38%)
2 154 (20%) 1609 (20%) 1770 (20%)
3 248 (32%) 2186 (28%) 2439 (28%)
4 138 (18%) 1067 (14%) 1210 (14%)
CD4 count, cells/mm3 12
<50 42 (19%) 745 (15%) –
50–99 14 (6%) 609 (12%) –
100–199 23 (10%) 1001 (20%) –
200–349 47 (21%) 1107 (22%) –
350-499 24 (11%) 715 (14%) –
≥500 77 (34%) 873 (17%) –
CD4% <25% 13 193 (67%) – –
Results are number (column percentage of those with non-missing data) for categorical variables and median (interquartile range) for continuous variables. 1 Including 29 patients
with unknown age who are not included in the child/adult columns (and are excluded from the age row). 2 Missing for 1 child, 26 adults, and 53 persons overall. 3 Missing for 92
children, 965 adults, and 1082 persons overall. 4 Missing for 181 adults. 5 Missing for 3634 adults. 6 Percentage is of women; missing for 1608 women. 7 Missing for 521 adults.
8 Missing for 1594 adults. 9 Missing for 51 children, 426 adults, and 505 persons overall. 10 Missing for 1400 adults. 11 As measured at first clinical visit which may be some time
after registration, but 74% of participants had registration and clinical visit on same day. Missing for 40 children, 493 adults, and 538 persons overall. 12 Results for children are
among the 380 children aged ≥5 years at registration. Missing for 153 children aged ≥5 years at registration and 3326 adults. 13 Results are among the 433 children aged <5
years at registration. Missing for 146 children aged <5 years at registration.
Table 2: Summary of the variables collected in KIULARCO.
Data fields Variable list
Sociodemographic data Name, national ID number, gender, address, contact details, date of birth, marital status, number of children, occupation, educa-
tion, date of HIV diagnosis, where referred from, and informed consent.
Triage data Weight, height, blood pressure, heart rate, respiratory rate, oxygen saturation, temperature, and middle upper arm circumference,
and head circumference in children
Clinical visit data Mode of HIV transmission, HIV status of partner, disclosure, pregnancy, contraception, ART exposure, adherence, past medical
history, alcohol use, smoking history, drug allergies, actual complaints, physical examination, ICD-10 coded clinical diagnosis,
WHO stage, tuberculosis screening, immune reconstitution inflammatory syndrome, drug toxicity, treatment failure, ART prescrip-
tion, destination.
Laboratory data Date and time of blood collectionLaboratory tests requested by the clinicianBaseline and monitoring results, including CD4, full
blood counts, liver and renal function tests, Cryptococcus, tuberculosis, hepatitis, syphilis, malaria and other relevant results.Locali-
sation of the cryopreserved plasma sampleUsage of the cryopreserved sample and amount left, project, investigator and date
Medication ART, tuberculosis treatment, and prophylaxis regimens prescribed by the clinician and collected by the patient, date of initiation,
modification or stop, reasons for treatment switching or discontinuation, pill counting
Outcome Reason for stopping participation in the cohort, information on transfer to another clinic, ICD-10 coded cause of death, place of
death.
ART = antiretroviral treatment; HIV = human immunodeficiency virus; ICD-10 = International classification of Diseases, 10th edition; WHO = World Health Organization
Original article Swiss Med Wkly. 2017;147:w14485
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 4 of 9
tions that may condition ART timing (mainly tuberculosis
and cryptococcosis) are evaluated by the clinician. If crite-
ria for ART initiation are met, patients receive three coun-
selling sessions, together with a next of kin to serve as a
treatment supporter, with the aim of starting ART within
a week. With the recent implementation of the test and
treat strategy, the first counselling visit occurs on the same
day and two more sessions are provided after the start
of treatment. Further clinical visits for treatment response
and possible drug toxicity are scheduled at 2 weeks and 3
months after ART initiation, and every 6 months thereafter.
In addition, patients are encouraged to attend the clinic in
the event of any problem.
Functioning of the CDCI
The CDCI was initially built to support the Tanzanian na-
tional AIDS control programme. Since 2013, the activities
at the CDCI have been progressively expanded to take care
of all out- and inpatients with HIV attended at the Saint
Francis Referral Hospital, including pregnant women, ado-
lescents, children, and HIV-exposed and HIV-infected in-
fants. Also, the CDCI participates in the supervision and
training of national and international medical students and
residents and the staff of other HIV care and treatment cen-
tres in the Kilombero district, and in delivering educational
activities to the community, such as radio broadcasts.
Key features of the CDCI are: (i) integration of services;
(ii) paperless functioning; (iii) task shifting; and (iv) de-
centralisation of services.
Integration of Services
Tuberculosis
In order to maximise the bidirectional screening and treat-
ment of these two often fatally associated diseases (HIV
and tuberculosis), in 2013 the tuberculosis clinic of Saint
Francis Referral Hospital was integrated into the CDCI,
which now provides outpatient and inpatient tuberculosis
care. The integration of services has resulted in improved
diagnostics (e.g., systematic application of WHO screen-
ing questions, improvement of procedures to provide qual-
itatively good sputum, and implementation of Xpert MTB/
RIF for the rapid diagnosis of tuberculosis, and of sonogra-
phy to detect signs of extrapulmonary tuberculosis). With
this, an improvement of the ascertainment of tuberculosis
cases within the clinic was noted (fig. 3), with no evidence
of any change in the true prevalence in the population.
Figure 3: Incidence rate of tuberculosis ascertainment before and
after the integration of HIV and tuberculosis services in 2013
(adapted from [26]).
The One Stop Clinic of Ifakara
A maternal and paediatric unit of the CDCI was created
and integrated within the Reproductive and Child health
Clinic of SFRH in 2013 with the following objectives:
(i) to improve linkage to care of HIV-infected pregnant
women; (ii) to increase uptake of the guidelines on pre-
vention of mother-to-child transmission of HIV and early
infant diagnosis; and (iii) to improve clinical outcomes of
pregnant women, HIV-exposed and HIV-infected children
(fig. 4) [27].
Medical wards
Since 2014, all patients admitted to the Saint Francis Re-
ferral Hospital wards without a prior HIV test are offered
HIV provider-initiated testing and counselling. Medical
doctors from the CDCI are fully responsible for inpatient
care of those identified as HIV positive, and invite patients
to enrol in KIULARCO. The same electronic data capture
methods as those in the main clinic are used by CDCI staff
in the wards through portable electronic devices, in order
to extend the clinical benefits of this system to admitted
patients and not to miss relevant information during admis-
sion (fig. 5).
Task shifting from doctors to nurses
Since 2013, all patients visiting the outpatient CDCI are
first seen by a registered nurse, who measures vital signs
and checks for symptoms. Asymptomatic patients with no
scheduled clinical visit with the medical doctor are sent di-
rectly to the pharmacy to collect refills of any current pre-
scriptions, which are given for three months if good adher-
ence can be ensured, until the next scheduled laboratory
monitoring and clinical visit. This task-shifting from doc-
tors to nurses has resulted in a decrease in the workload
of clinicians, who are now able to focus on sicker patients.
During visits with CD4 and viral load monitoring, med-
ical doctors see patients and communicate results to the pa-
tients. To cope with increasing numbers of patients on ART
without compromising efficacy, a rethinking of this system
to further capacitate nurses to initiate ART and to see sta-
ble patients on ART during their monitoring visits will be
needed.
Decentralisation of services
The CDCI supervises peripheral HIV care and treatment
centres in the Kilombero District, offering regular training
and a referral system for sick patients and medical condi-
tions that cannot be managed at peripheral health centres.
Figure 4: The One Stop Clinic of Ifakara integrates health services
for HIV-infected children, pregnant women, HIV-exposed infants
and their families (adapted from [27]). HIV = human immunodefi-
ciency virus; PITC = Provider Initiated Testing and Counselling
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In addition, a phone line has been established with the One
Stop Clinic of Ifakara that offers clinical consultations by
phone regarding pregnant women and children living with
HIV. Further decentralisation of services for the manage-
ment of stable patients will be needed to cope with the ex-
pected increase in workload resulting from the adoption of
the test and treat strategy.
Laboratory infrastructure
The CDCI provides basic laboratory services for the diag-
nosis and monitoring of HIV infection and comorbidities.
This includes phlebotomy services, HIV rapid tests, HIV
pro-viral DNA polymerase chain-reaction tests for early
infant diagnosis of HIV, complete blood count, liver and
renal function tests, CD4 counts, plasma HIV viral load,
HIV genotyping, Xpert Mycobacterium tuberculosis / re-
sistance to rifampicin (MTB/RIF) tests for the diagnosis
of tuberculosis, cryptococcal antigen lateral flow assay, he-
patitis B surface antigen, malaria blood slide and rapid test,
VDRL for syphilis diagnostics, analysis of cerebrospinal
and other sterile fluids originating from punctures, urine
and stool analysis. All test results are entered into the elec-
tronic data collection system and can be consulted by the
clinicians of the CDCI on the same day.
Key findings and scientific work publications
Research using KIULARCO data spans several relevant
areas. Some examples follow.
Treatment outcomes
A recent prospective study aiming to improve ART adher-
ence identified high levels of viral suppression (91%) and
adherence (over 90%) measured both by self-reported ad-
herence and by plasma therapeutic drug monitoring among
300 adults on ART for more than 6 months [28]. Analysis
of acquisition of HIV drug resistance mutations among this
same population identified a 5.6% prevalence of resistance
mutations [29]. In contrast, the proportion of children fail-
ing ART was 25%, and the majority harboured HIV drug-
resistance mutations, with multiclass resistances in 79% of
failing patients [30]. This study highlights the vulnerability
of the paediatric population to treatment failure and resis-
tance development, and the urgent need for universal viral
load monitoring.
Opportunistic infections
A study assessing the impact of the recent developments
of the CDCI in tuberculosis ascertainment found that the
integration of HIV and tuberculosis services, together with
the electronic data collection and reporting system and
the availability of Xpert MTB/RIF for diagnosis, resulted
in a 15-fold increase in the ascertainment of tuberculosis
among adults living with HIV enrolled in the cohort [26]
(fig. 3). This reinforces the need for the integration of ser-
vices at a national level. Studies on cryptococcosis showed
a prevalence of 4.4% among adults with CD4 count below
100 cells/mm3 when cryopreserved samples were retro-
spectively analysed, and being cryptococcal antigen
(CrAg) positive was an independent predictor of mortality
[31]. This study was one of the first showing a potential
survival benefit of treating cryptococcaemia with flucona-
zole. A subsequent prospective study conducted in KI-
ULARCO showed a higher CrAg prevalence among in-
patient adults and a reduction of mortality among CrAg-
positive patients without meningitis as a result of the im-
plementation of CrAg screening followed by fluconazole
treatment [32]. A pilot CrAg screening strategy has been
tested at district level [33], and a novel treatment strategy
Figure 5: Data capture at the medical wards. © Francesco Marzoli.
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for cryptococcal meningitis tailored to rural SSA was suc-
cessfully evaluated in an open-label clinical trial [34].
Comorbidities
A study aiming to assess the burden of hypertension
among KIULARCO participants aged >15 years showed
a 12% prevalence at enrolment in the cohort, and an ad-
ditional 10% developed hypertension during the first 6
months on ART. This study highlights the urgent need
for integrating HIV and noncommunicable disease care
[35]. Studies assessing the burden of liver disease iden-
tified a 9% prevalence of co-infection with hepatitis B
(HBV) among adults as well as a good correlation between
the HBV surface antigen rapid test and the enzyme-linked
immunosorbent assay (ELISA) [36]. A subsequent study
identified a high prevalence of advanced liver fibrosis and
cirrhosis before ART initiation assessed through the aspar-
tate transaminase (AST) to platelets ratio index (APRI) in
the general HIV adult population, and especially among
HIV-HBV co-infected individuals [37]. No cases of hepati-
tis delta were identified in our cohort [38].
Maternal and paediatric HIV
A situation analysis in 2012 assessing the implementation
of prevention of mother-to-child transmission of HIV un-
der programmatic circumstances identified several gaps to
be addressed [39]. The identification of these gaps led to
the development of the One Stop Clinic of Ifakara, an in-
tegrated service delivery model of maternal and paediatric
HIV services (fig. 4). This strategy resulted in an increased
number of mothers and children diagnosed and linked into
care, a higher detection of children with AIDS, universal
treatment coverage, lower loss to follow-up, and an ear-
ly mother-to-child transmission rate below the threshold of
elimination of 5%. This study documents a feasible, ef-
fective and scalable model for family-centred HIV care in
SSA [27].
Mortality and loss to follow up
A study describing the status of the cohort over the decade
since its initiation found, in nearly 8000 individuals, 5-year
mortality rates of 10 and 12% among adults and children,
respectively, and corresponding lost to follow up rates of
44 and 40% [40]. These results are consistent with the na-
tional data [18] and reports from other cohorts [41]. On-go-
ing work investigates factors associated with attrition, us-
ing tracing information to correct mortality estimates for
the unseen deaths among those lost to follow up.
Ongoing and future projects
Current and future KIULARCO projects focus on persist-
ing challenges, such as the high rate of attrition mentioned
above, the characterisation of HIV drug resistance to sec-
ond-line ART, and the study of advanced HIV disease and
comorbidities. KIULARCO also serves as a platform for
prospective studies on several relevant topics, including
the rollout of early HIV infant diagnosis in the district,
ART adherence among adolescents living with HIV, ac-
ceptability and tolerance of new paediatric ART formula-
tions, improvement of tuberculosis diagnostics, and early
detection and management of cryptococcal infection. Fi-
nally, projects to up-build the test and treat strategy in the
community, and linkage and retention in care are planned.
Main strengths and weaknesses
KIULARCO has several strengths that make it a valuable
research asset while contributing to the strengthening of
clinical care and building local capacity to deal with the
challenges posed by the HIV/AIDS pandemic in rural
SSA. The most important strength is the in-built managed
care for patients with a research-based feedback system.
The quality of clinical care, including diagnostic, treatment
and laboratory aspects, are constantly analysed, enabling
regular feedback to the team of the CDCI. In particular,
the feedback concerning loss to follow up, ART adherence,
HIV drug resistances, and opportunistic infections and co-
morbidities is essential to increase the quality of care. In
addition, data gathered by the studies conducted within KI-
ULARCO are used to refine the care and treatment proto-
cols in place. Further strengths are the prospective charac-
ter of the cohort study, the comprehensiveness of the data
collected using standardised electronic questionnaires and
the high quality of real-time patient-level data. This system
allows critical questions to be answered prospectively un-
der programmatic circumstances. Moreover, the flexibili-
ty of the data collection system allows new data collection
modules to be added for substudies of interest. Remark-
ably, KIULARCO is the largest and most comprehensive
single-site cohort in Tanzania, and among the largest in
rural sub-Saharan Africa. Having large volume patient-lev-
el comprehensive clinical data is key to answering rele-
vant questions that may be more difficult to solve through
pooled data sets, which are also limited by heterogeneity
between the different cohorts included. Another strength is
the availability of a plasma biobank, which allows analy-
sis of temporal trends or testing of samples retrospectively
in the laboratory. Finally, this is an open, ongoing cohort,
and enrolment of patients continues, making KIULARCO
an invaluable platform to implement evidence-based inter-
ventions and to evaluate their impact on clinical outcomes
prospectively, as well as to test new interventions through
randomised clinical trials.
KIULARCO also has weaknesses. As a result of the low
availability of diagnostic tools, some conditions are under-
reported and need to be interpreted and analysed with cau-
tion. Also, because of the high mobility of our population,
there is a high rate of silent transfer of patients to other
clinics, as well as loss to follow up [40]. New systems of
active follow up, decentralisation of services and commu-
nity involvement will need to be implemented to cope with
this important challenge that threatens the global control of
the HIV epidemic.
In conclusion, KIULARCO is a dynamic and very valuable
prospective observational cohort study that serves clinical
and translational research and, importantly, contributes to
improving the clinical setup and the wellbeing of PLWHIV
attending the CDCI. In our view, the strengths of KIU-
LARCO largely outweigh its weaknesses, and we believe
that KIULARCO may serve as a model for strengthening
clinical care in similar settings in SSA. Finally, in addition
to improving clinical care and generating relevant infor-
mation, such integrated models adapted to the loco-region-
al needs offer career opportunities for healthcare person-
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nel and thus help overcoming the human resource crisis in
healthcare in rural SSA.
How to collaborate with KIULARCO and fur-
ther information
National and international collaborations, interests and en-
quiries relating to KIULARCO are encouraged, and can be
addressed to Prof. Christoph Hatz (Christoph.Hatz@uni-
bas.ch), Prof. Manuel Battegay (Manuel.Batte-
gay@usb.ch) and Mr Frederick Masanja (fmasan-
ja@ihi.or.tz). Only relevant research questions in line with
the objectives of KIULARCO will be considered. Letters
of intent (LOI) are evaluated every two months by the
KIULARCO scientific committee, and researchers of ap-
proved LOIs are invited to develop full proposals. Success-
ful applicants are given access to the relevant KIULAR-
CO data for the project by the data managers once a data
sharing agreement is signed. All participating institutions
who conduct analyses on the data should seek their own
ethics approval at the relevant Tanzanian and international
boards, using de-identified data.
Further information and contact details about the Chronic
Diseases of Ifakara and the KIULARCO cohort can be
found at https://www.swisstph.ch/de/projects/tanzania-
chronic-disease-clinic-ifakara/ and http://ihi.or.tz/chronic-
diseases-care-treatment-centre/.
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